Bladder transitional cell carcinoma
Not recruitingStudy on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy
Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy
- Disease:Bladder transitional cell carcinoma
- Substances:CetrelimabGemcitabine Hydrochloride
Italy- Participants:18–64 years · 65+ years
- Substances:Cetrelimab
- Sponsor:Janssen Cilag International













